Related Experiment Video

Updated: May 13, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

[Multidrug resistance-related proteins and their relationship with acute leukemia]

Zhi Li1, Bao-An Chen

  • 1Department of Hematology and Oncology, Southeast University Medical School, Nanjing, Jiangsu Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|March 15, 2013
PubMed

Insights

Multidrug resistance-related proteins (MRP) are ATP-dependent efflux pumps linked to chemotherapy failure in cancers. Their role in acute leukemia requires further research, but understanding MRP is crucial for treatment outcomes.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Context:

  • Multidrug resistance-related proteins (MRP) are ATP-dependent efflux pumps implicated in multidrug resistance (MDR).
  • Abnormal MRP expression is associated with chemotherapy failure in various malignancies.
  • The specific role of MRP in acute leukemia pathogenesis and treatment remains incompletely understood due to limited research.

Purpose:

  • To review the current understanding of Multidrug resistance-related proteins (MRP).
  • To explore the structure, distribution, and function of MRP.
  • To elucidate the relationship between MRP, multidrug resistance (MDR), and the prognosis of acute leukemia.

Summary:

  • This review consolidates existing knowledge on Multidrug resistance-related proteins (MRP), focusing on their function as ATP-dependent efflux pumps.
  • It examines the link between MRP expression abnormalities and multidrug resistance (MDR), a common cause of chemotherapy failure in cancers.
  • The article specifically addresses the current gaps in understanding MRP's involvement in acute leukemia, highlighting the need for further experimental and clinical investigation.

Impact:

  • Provides a comprehensive overview of MRPs and their established role in MDR.
  • Highlights the critical need for further research into MRPs in the context of acute leukemia.
  • Informs potential therapeutic strategies by clarifying MRP's influence on acute leukemia prognosis and chemotherapy response.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...